ArticleHistopathology2018
Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort.
Article in Histopathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 63 citations in OpenAlex.
- Tall Cell Carcinoma With Reversed Polarity of the Breast: A Case Report.Journal of breast cancer · 2026Article
- Tall Cell Carcinoma of the Breast With Reverse Polarity: Expanding the Molecular Spectrum WithClinical case reports · 2026Article
- Evaluation of the Idylla IDH1-2 Mutation Assay for the Detection ofInternational journal of molecular sciences · 2026Article
- Seven Shades of Triple Negativity: A Review Unveiling the Low-Grade Spectrum of Breast Cancer.Cancers · 2025Review
- Tall cell carcinoma with reverse polarity of the breast in a young patient: A case report.International journal of surgery case reports · 2025Article
- Tall cell carcinoma with reversed polarity of breast cancer: a rare case report and review of the literature.Frontiers in oncology · 2025Article
- Exploration of Traditional Chinese Medicine Comprehensive Treatment of Triple Negative Breast Cancer Based on Molecular Pathological Mechanism.Breast cancer (Dove Medical Press) · 2025Review
- Clinicopathological characterization of tall cell carcinoma with reversed polarity of the breast: A case report and review of the litterature.International journal of surgery case reports · 2024Article
- Breast Cancer Subtypes: Clinicopathologic Features and Treatment Considerations.Current breast cancer reports · 2024Article
- Case report: Triple-negative breast cancer with low tumour-infiltrating lymphocytes infiltration and good prognosis: a case of Tall Cell Carcinoma with Reversed Polarity and review of the literature.Frontiers in oncology · 2024Article
- Case report: Tall cell carcinoma with reversed polarity of the breast: an additional case and review of the literature.Frontiers in oncology · 2024Article
- Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023.Breast care (Basel, Switzerland) · 2023Review
- Review
- AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022.Breast care (Basel, Switzerland) · 2022Review
- Breast carcinomas of low malignant potential.Virchows Archiv : an international journal of pathology · 2022Review
- Narrative review of progress in pathological diagnosis of breast cancer.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2022Review
- Triple-negative breast carcinomas of low malignant potential: review on diagnostic criteria and differential diagnoses.Virchows Archiv : an international journal of pathology · 2022Review
- Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.Cell reports. Medicine · 2021Review
- Isocitrate dehydrogenase gene variants in cancer and their clinical significance.Biochemical Society transactions · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 4 countries.
Funding
Abstract
aimsSolid papillary breast carcinoma resembling the tall cell variant of papillary thyroid neoplasms (BPTC), also known as solid papillary carcinoma with reverse polarity, is a rare histological type of breast cancer that resembles morphologically the tall cell variant of papillary thyroid carcinoma. BPTCs are characterised by IDH2 R172 hotspot somatic mutations or mutually exclusive TET2 somatic mutations, concurrently with mutations affecting PI3K pathway-related genes. We sought to characterise their histology and investigate the frequency of IDH2 and PIK3CA mutations in an independent cohort of BPTCs, as well as in conventional solid papillary carcinomas (SPCs). METHODS AND
resultsSix BPTCs, not previously analysed molecularly, and 10 SPCs were reviewed centrally. Tumour DNA was extracted from microdissected histological sections and subjected to Sanger sequencing of the IDH2 R172 hotspot locus and exons 9 and 20 of PIK3CA. All six BPTCs were characterised by solid, papillary and follicular architecture with circumscribed, invasive tumour nodules composed of epithelial cells with reverse polarity. IDH2 mutations were identified in all six BPTCs (three R172S, two R172T and one R172G), four of which also harboured PIK3CA mutations (two H1047R, one Q546K and one Q546R). By contrast, all SPCs lacked IDH2 mutations, while one of 10 harboured a PIK3CA mutation (H1047R).
conclusionWe validated the presence of IDH2 R172 hotspot mutations and PIK3CA hotspot mutations in 100% and 67% BPTCs tested, respectively, and documented absence of IDH2 R172 mutations in SPCs. These findings confirm the genotypical-phenotypical correlation reported previously in BPTC, which constitutes an entity distinct from conventional SPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.